Acute Myeloid Leukemia | Disease Landscape & Forecast | G7 | 2024
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent approval of new drugs, such as Vanflyta (a second-generation FLT-3 inhibitor) and Rezlidhia (an IDH1 inhibitor), indicates a trend toward targeted therapies. Moreover, both early- and late-phase pipelines for AML include various drug classes such as kinase inhibitors, radio-immunotherapeutics, menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. With the expected approval of several new treatments and the expansion of existing ones into additional patient populations, we expect substantial growth of the AML drug therapy market.
Questions answered:
- How large are the clinically and commercially relevant drug-treatable AML populations, and how will drug-treatable rates change (if at all) over the 2023-2033 forecast period?
- What is the current treatment landscape for AML? What are the key takeaways from expert interviews?
- What are the most promising therapies in the pipeline, and how will they influence the AML therapy market?
- What are the primary factors driving and limiting the AML market, and how will this market evolve over the forecast period?
Geographies: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence cases of AML by country and by clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level, and regimen-level sales and patient share of key AML therapies through 2033, segmented by brands / generics / biosimilars and drug-treatable subpopulations.
Drug treatments: Coverage of key current and emerging therapies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
